Immutep (ASX:IMM) OCF Margin %: 0.00% (As of Dec. 2025)


What is Immutep OCF Margin %?

Immutep ASX:IMM -5.88% OCF Margin % is 0.00% as of Dec. 2025. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, Immutep ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Immutep's Cash Flow from Operations for the three months ended in Dec. 2025 was A$-9.61 Mil. Immutep's Revenue for the three months ended in Dec. 2025 was A$0.00 Mil. Therefore, Immutep's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Immutep's current OCF Yield % is -44.40%.

The historical rank and industry rank for Immutep's OCF Margin % or its related term are showing as below:


During the past 13 years, the highest OCF Margin % of Immutep was -144.79%. The lowest was -17782.35%. And the median was -6462.86%.

ASX:IMM's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Immutep OCF Margin % Related Terms

Immutep OCF Margin % Historical Data

* Premium members only.

The historical data trend for Immutep's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immutep OCF Margin % Chart

Immutep Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -17,782.35 0.00 0.00 0.00

Immutep Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Immutep OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Immutep's OCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-62.05/0
= %

Immutep's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-9.613/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Immutep (ASX:IMM) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Immutep and its competitors. According to the industry distribution chart, Immutep ranks #999999 out of 959 companies in the Biotechnology industry.
Is Immutep's OCF Margin % too high?
Immutep's current OCF Margin % is 0.00%. Based on the distribution chart, Immutep ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Immutep's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immutep ranks #999999 out of 959 companies for OCF Margin %. This places Immutep in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Immutep and its competitors. Immutep's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immutep stock overvalued right now?
Immutep (ASX:IMM) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Immutep (ASX:IMM), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immutep Business Description

Address 264 George Street, Level 32, Australia Square, Sydney, NSW, AUS, 2000
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.